|
|
|
|
|
Teniposide
drug data and news
Teniposide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Teniposide | ||
| Brand Names/Synonyms | CCRIS 2058; EPT; Etoposide; Etoposide Usp26; HSDB 6546; PTG; Teniposide; Teniposide [Usan:Ban:Inn]; Teniposido [Inn-Spanish]; Teniposidum [Inn-Latin]; VM 26; VM-26; Vee M-26; Veham-Sandoz; Vehem; Vumon | ||
| Indication | Treatment of refractory acute lymphoblastic leukaemia | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Teniposide is a phase-specific cytotoxic drug, acting in the late S or early G 2 phase of the cell cycle, thus preventing cells from entering mitosis. Teniposide causes dose-dependent single- and double-stranded breaks in DNA and DNA: protein cross-links. The mechanism of action appears to be related to the inhibition of type II topoisomerase activity since teniposide does not intercalate into DNA or bind strongly to DNA. | ||
| Mechanism Of Action | Binds to and inhibits DNA topoisomerase II. The cytotoxic effects of teniposide are related to the relative number of double-stranded DNA breaks produced in cells, which are a reflection of the stabilization of a topoisomerase II-DNA intermediate. | ||
| Teniposide News (When available) |
| ||
| Dosage Forms | LIQUID | ||
| Drug_Category | Antineoplastic Agents; ATC:L01CB02 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Teniposide: Drug Interactions: In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. Because of the extremely high binding of teniposide to plasma proteins, these small decreases in binding could cause substantial increases in free drug levels in plasma which could result in potentiation of drug toxicity. Therefore, caution should be used in administering VUMON (teniposide injection) to patients receiving these other agents. There was no change in the plasma kinetics of teniposide when coadministered with methotrexate. However, the plasma clearance of methotrexate was slightly increased. An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C32H32O13S | ||
| Molecular Weight | 656.655 g/mol | ||
| Smiles String | COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)OC6C(C(C7C(O6)COC(O7)C8=CC=CS8)O)O | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 1.963 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 5 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Teniposide.html http://www.rxlist.com/cgi/generic2/teniposide.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00649 | ||
| CAS Registry Number | 29767-20-2 | ||
| KEGG Compound ID | C11153 | ||
| PubChem ID | SID:176397 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 588989 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |